US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BioAge Labs Inc.

9.52

+0.02000.21%

Post-market: 9.520.00000.00%16:10 EDT

Volume:604.99K

Turnover:5.76M

Market Cap:436.94M

PE:-4.02

High:9.72

Open:9.28

Low:9.15

Close:9.50

52wk High:25.96

52wk Low:4.55

Shares:45.90M

Float Shares:37.58M

Volume Ratio:1.02

T/O Rate:1.61%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3710

EPS(LYR):-2.2432

ROE:-28.21%

ROA:-18.47%

PB:1.17

PE(LYR):-4.24

Loading ...

Overview Company News Filings

BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating

BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2

BioAge Shares Rise on Positive Trial Data

BioAge Labs Says Drug Candidate Shows 'Best-in-Class Reductions' in Inflammatory Biomarkers in Phase 1 Trial With Obese Patients

MT Newswires Live

Bioage Labs: Reports Positive Phase 1 Data for Bge-102

THOMSON REUTERS

Bioage Labs Inc - Phase 2 Cardiovascular Risk Trial to Initiate Mid-2026, Results Expected End 2026

THOMSON REUTERS

Bioage Labs Inc - Bge-102 Well Tolerated Across All Dose Levels

THOMSON REUTERS

Bioage Labs Inc - Bge-102 Achieves ≥85% Median Hscrp Reductions at 120 Mg and 60 Mg Doses in Obesity

THOMSON REUTERS

BioAge reports Phase 1 data for BGE-102, showing 85% hsCRP reduction

BioAge Labs to present at Needham Virtual Healthcare Conference

BioAge Labs CMO Paul D. Rubin disposes of common shares worth $0.2 million

Needham Initiates BioAge Labs at Buy With $50 Price Target

MT Newswires Live

Bioage Labs Inc : Needham Initiates Coverage With Buy Rating; Target Price $50

THOMSON REUTERS

BioAge Labs Initiated at Buy by Needham

U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings

BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating

BioAge Labs files automatic mixed securities shelf

Bioage Labs Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS

BioAge Announces Lead Program BGE-102 NLRP3 Inhibitor Candidate

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/BIOA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIOA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":9.52,"timestamp":1788292800000,"preClose":9.5,"halted":0,"volume":604993,"hourTrading":{"tag":"盘后","latestPrice":9.52,"preClose":9.52,"latestTime":"16:10 EDT","volume":5043,"amount":48009.36,"timestamp":1788293404773,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.002105263157894692,"floatShares":37575608,"shares":45896909,"eps":-2.371024,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"09-01 18:27:46 EDT","open":9.28,"high":9.72,"low":9.1501,"amount":5757653,"amplitude":0.059989,"askPrice":10,"askSize":50,"bidPrice":9.33,"bidSize":18,"shortable":3,"etf":0,"ttmEps":-2.371024,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":9.5,"preHourTrading":{"tag":"盘前","latestPrice":9.21,"preClose":9.5,"latestTime":"09:25 EDT","volume":927,"amount":8601.102756,"timestamp":1788269118255,"change":-0.29,"changeRate":-0.030526,"amplitude":0.035474},"postHourTrading":{"tag":"盘后","latestPrice":9.52,"preClose":9.52,"latestTime":"16:10 EDT","volume":5043,"amount":48009.36,"timestamp":1788293404773,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.020596,"impliedVol":1.4537,"impliedVolPercentile":0.8651},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","floatShares":37575608,"roa":"-18.47%","roe":"-28.21%","lyrEps":-2.243207,"volumeRatio":1.020596,"shares":45896909,"dividePrice":0,"high":9.72,"amplitude":0.059989,"preClose":9.5,"low":9.1501,"week52Low":4.55,"pbRate":"1.17","psRate":"42.20","week52High":25.955,"institutionHeld":0,"latestPrice":9.52,"committee":-0.470588,"eps":-2.371024,"divideRate":0,"volume":604993,"delay":0,"ttmEps":-2.371024,"open":9.28,"prevYearClose":13.23,"prevWeekClose":9.65,"prevMonthClose":9.5,"prevQuarterClose":24.51,"fiveDayClose":10.11,"twentyDayClose":11.2,"sixtyDayClose":15.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIOA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"BIOA","fiscalQuarterEnding":"2026/06","expectedEps":-0.65,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":-0.58},{"market":"US","date":"2026-05-08","symbol":"BIOA","fiscalQuarterEnding":"2026/03","expectedEps":-0.71,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-03-24","symbol":"BIOA","fiscalQuarterEnding":"2025/12","expectedEps":-0.83,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-06","symbol":"BIOA","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.56},{"market":"US","date":"2025-08-06","symbol":"BIOA","fiscalQuarterEnding":"2025/06","expectedEps":-0.56,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIOA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIOA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4444,"buy":0.3333,"hold":0.2222,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":9,"updateTime":1779940800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BIOA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BIOA","date":"2026-08-31","current":-4.015143,"percent":0.480249,"low":-14.88445,"twenty":-10.411692,"median":-4.158354,"eighty":-2.193597,"high":-1.532635,"avg":-5.917783,"sd":3.969194,"marketCap":442905171},"quantilePoints":[{"date":"2024-09-27","current":-10.065016,"twenty":-9.996853,"median":-9.894609,"eighty":-9.328936,"marketCap":625601139},{"date":"2024-10-04","current":-11.466752,"twenty":-11.453559,"median":-10.988513,"eighty":-9.962772,"marketCap":712727458},{"date":"2024-10-11","current":-11.290848,"twenty":-11.83725,"median":-11.290848,"eighty":-10.377246,"marketCap":701793959},{"date":"2024-10-18","current":-13.247909,"twenty":-12.852074,"median":-11.505231,"eighty":-10.913754,"marketCap":823437060},{"date":"2024-10-25","current":-13.708907,"twenty":-13.699687,"median":-12.032944,"eighty":-11.062173,"marketCap":852090807},{"date":"2024-10-31","current":-14.198716,"twenty":-13.910593,"median":-12.258321,"eighty":-11.163318,"marketCap":882535413},{"date":"2024-11-08","current":-10.411209,"twenty":-13.841443,"median":-12.631325,"eighty":-11.163318,"marketCap":738550334},{"date":"2024-11-15","current":-9.850761,"twenty":-13.741177,"median":-12.203351,"eighty":-10.879672,"marketCap":698793259},{"date":"2024-11-22","current":-9.318711,"twenty":-13.704297,"median":-11.736106,"eighty":-10.071646,"marketCap":661050728},{"date":"2024-11-29","current":-9.500638,"twenty":-13.685857,"median":-11.456511,"eighty":-9.850761,"marketCap":673956274},{"date":"2024-12-06","current":-9.283336,"twenty":-13.657045,"median":-11.290848,"eighty":-9.500638,"marketCap":658541317},{"date":"2024-12-13","current":-2.319571,"twenty":-13.258776,"median":-11.073716,"eighty":-9.298497,"marketCap":164545707},{"date":"2024-12-20","current":-2.612676,"twenty":-13.247909,"median":-10.411209,"eighty":-9.141838,"marketCap":185337975},{"date":"2024-12-27","current":-2.971476,"twenty":-13.224859,"median":-10.152544,"eighty":-7.606575,"marketCap":210790579},{"date":"2025-01-03","current":-2.809763,"twenty":-13.09117,"median":-10.065016,"eighty":-3.032119,"marketCap":199318983},{"date":"2025-01-10","current":-2.572247,"twenty":-12.858367,"median":-9.894609,"eighty":-2.886577,"marketCap":182470076},{"date":"2025-01-17","current":-2.54698,"twenty":-12.632478,"median":-9.680039,"eighty":-2.714757,"marketCap":180677639},{"date":"2025-01-24","current":-2.678371,"twenty":-12.552115,"median":-9.568861,"eighty":-2.625815,"marketCap":189998311},{"date":"2025-01-31","current":-2.415588,"twenty":-12.247327,"median":-9.318711,"eighty":-2.600547,"marketCap":171356967},{"date":"2025-02-07","current":-2.309464,"twenty":-12.16927,"median":-9.263122,"eighty":-2.51868,"marketCap":163828732},{"date":"2025-02-14","current":-2.284196,"twenty":-12.012055,"median":-9.141838,"eighty":-2.417609,"marketCap":162036295},{"date":"2025-02-21","current":-2.223554,"twenty":-11.928501,"median":-8.818412,"eighty":-2.37516,"marketCap":157734447},{"date":"2025-02-28","current":-2.208393,"twenty":-11.54371,"median":-3.087708,"eighty":-2.319571,"marketCap":156658985},{"date":"2025-03-07","current":-2.269035,"twenty":-11.466752,"median":-2.971476,"eighty":-2.294303,"marketCap":160960833},{"date":"2025-03-14","current":-2.122483,"twenty":-11.446271,"median":-2.893147,"eighty":-2.269035,"marketCap":150564699},{"date":"2025-03-21","current":-2.208204,"twenty":-11.43377,"median":-2.779442,"eighty":-2.233661,"marketCap":157023162},{"date":"2025-03-28","current":-1.956126,"twenty":-11.290848,"median":-2.7188,"eighty":-2.233661,"marketCap":139098143},{"date":"2025-04-04","current":-1.714131,"twenty":-11.203915,"median":-2.693532,"eighty":-2.213447,"marketCap":121890125},{"date":"2025-04-11","current":-1.729255,"twenty":-11.131435,"median":-2.645523,"eighty":-2.198286,"marketCap":122965626},{"date":"2025-04-17","current":-1.890585,"twenty":-11.039085,"median":-2.589935,"eighty":-2.192221,"marketCap":134437638},{"date":"2025-04-25","current":-2.117456,"twenty":-10.879672,"median":-2.54698,"eighty":-2.170997,"marketCap":150570155},{"date":"2025-05-02","current":-2.087206,"twenty":-10.498085,"median":-2.486337,"eighty":-2.155781,"marketCap":148419153},{"date":"2025-05-09","current":-2.073948,"twenty":-10.229442,"median":-2.420641,"eighty":-2.117456,"marketCap":147343652},{"date":"2025-05-16","current":-1.927611,"twenty":-10.158835,"median":-2.377687,"eighty":-2.112406,"marketCap":136947141},{"date":"2025-05-23","current":-2.038626,"twenty":-10.109042,"median":-2.344838,"eighty":-2.086198,"marketCap":144834149},{"date":"2025-05-30","current":-2.008349,"twenty":-10.078276,"median":-2.334731,"eighty":-2.073148,"marketCap":142683147},{"date":"2025-06-06","current":-2.24047,"twenty":-9.99928,"median":-2.314518,"eighty":-2.051746,"marketCap":159174164},{"date":"2025-06-13","current":-2.2657,"twenty":-9.918948,"median":-2.294303,"eighty":-2.064674,"marketCap":160966666},{"date":"2025-06-20","current":-2.215239,"twenty":-9.87707,"median":-2.284196,"eighty":-2.072748,"marketCap":157381662},{"date":"2025-06-27","current":-2.200101,"twenty":-9.785504,"median":-2.271562,"eighty":-2.073948,"marketCap":156306161},{"date":"2025-07-03","current":-2.159732,"twenty":-9.684587,"median":-2.26468,"eighty":-2.075591,"marketCap":153438158},{"date":"2025-07-11","current":-2.361576,"twenty":-9.665383,"median":-2.263661,"eighty":-2.08254,"marketCap":167778173},{"date":"2025-07-18","current":-2.422129,"twenty":-9.609795,"median":-2.271562,"eighty":-2.08404,"marketCap":172080177},{"date":"2025-07-25","current":-2.371668,"twenty":-9.500638,"median":-2.280838,"eighty":-2.084673,"marketCap":168495173},{"date":"2025-08-01","current":-2.220285,"twenty":-9.464253,"median":-2.280838,"eighty":-2.088197,"marketCap":157740162},{"date":"2025-08-08","current":-1.959737,"twenty":-9.314668,"median":-2.269035,"eighty":-2.084673,"marketCap":154872159},{"date":"2025-08-15","current":-2.023247,"twenty":-9.295465,"median":-2.262157,"eighty":-2.074957,"marketCap":159891165},{"date":"2025-08-22","current":-2.041393,"twenty":-9.27525,"median":-2.258928,"eighty":-2.064982,"marketCap":161325166},{"date":"2025-08-29","current":-2.177486,"twenty":-9.225726,"median":-2.244642,"eighty":-2.064982,"marketCap":172080177},{"date":"2025-09-05","current":-2.136658,"twenty":-9.156998,"median":-2.24047,"eighty":-2.068612,"marketCap":168853674},{"date":"2025-09-12","current":-2.227387,"twenty":-9.141838,"median":-2.24047,"eighty":-2.071948,"marketCap":176023681},{"date":"2025-09-19","current":-2.368016,"twenty":-8.95182,"median":-2.24047,"eighty":-2.073948,"marketCap":187137193},{"date":"2025-09-26","current":-2.368016,"twenty":-8.818412,"median":-2.24047,"eighty":-2.073948,"marketCap":187137193},{"date":"2025-10-03","current":-2.676493,"twenty":-8.732502,"median":-2.244642,"eighty":-2.078994,"marketCap":211515218},{"date":"2025-10-10","current":-2.472354,"twenty":-3.102868,"median":-2.258928,"eighty":-2.082165,"marketCap":195382701},{"date":"2025-10-17","current":-2.318115,"twenty":-3.072547,"median":-2.260654,"eighty":-2.08404,"marketCap":183193689},{"date":"2025-10-24","current":-3.606461,"twenty":-3.072547,"median":-2.2657,"eighty":-2.08404,"marketCap":285007794},{"date":"2025-10-31","current":-3.50666,"twenty":-3.483977,"median":-2.271562,"eighty":-2.087206,"marketCap":277120786},{"date":"2025-11-07","current":-3.533398,"twenty":-3.483977,"median":-2.280838,"eighty":-2.091294,"marketCap":267799776},{"date":"2025-11-14","current":-3.65216,"twenty":-3.543352,"median":-2.287377,"eighty":-2.091294,"marketCap":276800885},{"date":"2025-11-21","current":-4.063738,"twenty":-3.690007,"median":-2.299357,"eighty":-2.092162,"marketCap":307994767},{"date":"2025-11-28","current":-4.489508,"twenty":-3.899107,"median":-2.309042,"eighty":-2.092231,"marketCap":340264301},{"date":"2025-12-05","current":-4.967317,"twenty":-4.069415,"median":-2.318115,"eighty":-2.105866,"marketCap":376477888},{"date":"2025-12-12","current":-6.031742,"twenty":-4.3315,"median":-2.319571,"eighty":-2.109405,"marketCap":457151721},{"date":"2025-12-19","current":-5.856703,"twenty":-5.07234,"median":-2.333015,"eighty":-2.111789,"marketCap":443885358},{"date":"2025-12-26","current":-6.660935,"twenty":-5.750734,"median":-2.336346,"eighty":-2.112399,"marketCap":504838920},{"date":"2026-01-02","current":-6.258819,"twenty":-5.908741,"median":-2.336346,"eighty":-2.11442,"marketCap":474362139},{"date":"2026-01-09","current":-6.585243,"twenty":-6.05445,"median":-2.344838,"eighty":-2.11744,"marketCap":499102115},{"date":"2026-01-16","current":-10.175903,"twenty":-6.388442,"median":-2.355734,"eighty":-2.117456,"marketCap":771241845},{"date":"2026-01-23","current":-10.411813,"twenty":-6.562534,"median":-2.368016,"eighty":-2.117456,"marketCap":789121720},{"date":"2026-01-30","current":-10.521991,"twenty":-6.660935,"median":-2.37516,"eighty":-2.117837,"marketCap":797472215},{"date":"2026-02-06","current":-11.006774,"twenty":-8.674889,"median":-2.403126,"eighty":-2.119987,"marketCap":834214390},{"date":"2026-02-13","current":-10.984738,"twenty":-9.153966,"median":-2.415588,"eighty":-2.124502,"marketCap":832544291},{"date":"2026-02-20","current":-11.094916,"twenty":-9.298497,"median":-2.422129,"eighty":-2.13258,"marketCap":840894786},{"date":"2026-02-27","current":-12.295855,"twenty":-9.537248,"median":-2.429257,"eighty":-2.136658,"marketCap":931915175},{"date":"2026-03-06","current":-11.22713,"twenty":-9.787979,"median":-2.458744,"eighty":-2.147751,"marketCap":850915379},{"date":"2026-03-13","current":-10.954439,"twenty":-10.064753,"median":-2.474292,"eighty":-2.150267,"marketCap":830247905},{"date":"2026-03-20","current":-11.590717,"twenty":-10.152544,"median":-2.496444,"eighty":-2.150267,"marketCap":878472010},{"date":"2026-03-27","current":-8.946976,"twenty":-10.175903,"median":-2.526002,"eighty":-2.154686,"marketCap":721170986},{"date":"2026-04-02","current":-9.761839,"twenty":-10.157216,"median":-2.545959,"eighty":-2.157168,"marketCap":786853020},{"date":"2026-04-10","current":-9.794874,"twenty":-10.109042,"median":-2.572155,"eighty":-2.15903,"marketCap":789515805},{"date":"2026-04-17","current":-9.354407,"twenty":-10.088448,"median":-2.581791,"eighty":-2.159654,"marketCap":754012003},{"date":"2026-04-24","current":-9.492053,"twenty":-10.157216,"median":-2.612676,"eighty":-2.159732,"marketCap":765106941},{"date":"2026-05-01","current":-9.281102,"twenty":-10.117474,"median":-2.677432,"eighty":-2.159732,"marketCap":748103216},{"date":"2026-05-08","current":-9.815385,"twenty":-10.117474,"median":-2.685566,"eighty":-2.162275,"marketCap":791169098},{"date":"2026-05-15","current":-9.250894,"twenty":-10.100274,"median":-2.711219,"eighty":-2.168441,"marketCap":831932916},{"date":"2026-05-22","current":-8.274644,"twenty":-10.088448,"median":-2.728907,"eighty":-2.172379,"marketCap":744138767},{"date":"2026-05-29","current":-8.427879,"twenty":-10.073417,"median":-2.779442,"eighty":-2.173018,"marketCap":757919114},{"date":"2026-06-05","current":-8.413049,"twenty":-10.064858,"median":-2.893147,"eighty":-2.175699,"marketCap":756585532},{"date":"2026-06-12","current":-8.131296,"twenty":-9.999175,"median":-2.971476,"eighty":-2.177486,"marketCap":731247474},{"date":"2026-06-18","current":-9.881131,"twenty":-10.021034,"median":-3.072547,"eighty":-2.177486,"marketCap":888610152},{"date":"2026-06-26","current":-11.18115,"twenty":-10.10449,"median":-3.377371,"eighty":-2.17969,"marketCap":1005520843},{"date":"2026-07-02","current":-11.991808,"twenty":-10.16483,"median":-3.4182,"eighty":-2.183022,"marketCap":1078423326},{"date":"2026-07-10","current":-12.30322,"twenty":-10.247258,"median":-3.447686,"eighty":-2.183492,"marketCap":1106428549},{"date":"2026-07-17","current":-10.953771,"twenty":-10.359979,"median":-3.495318,"eighty":-2.185281,"marketCap":985072585},{"date":"2026-07-24","current":-10.825252,"twenty":-10.509871,"median":-3.543352,"eighty":-2.186883,"marketCap":973514874},{"date":"2026-07-31","current":-12.283448,"twenty":-10.632169,"median":-3.606461,"eighty":-2.188179,"marketCap":1104650439},{"date":"2026-08-07","current":-5.30342,"twenty":-10.612701,"median":-3.697103,"eighty":-2.190009,"marketCap":500982312},{"date":"2026-08-14","current":-5.067589,"twenty":-10.521991,"median":-3.898161,"eighty":-2.190009,"marketCap":478704760},{"date":"2026-08-21","current":-4.708048,"twenty":-10.461393,"median":-3.973853,"eighty":-2.193232,"marketCap":444741048},{"date":"2026-08-28","current":-4.897536,"twenty":-10.411813,"median":-4.092123,"eighty":-2.193232,"marketCap":462640842},{"date":"2026-08-31","current":-4.688613,"twenty":-10.411692,"median":-4.158354,"eighty":-2.193597,"marketCap":442905171}],"updateTime":1788301666815},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIOA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629055586","title":"BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2629055586","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629055586?lang=en_us&edition=fundamental","pubTime":"2026-04-21 23:35","pubTimestamp":1776785720,"startTime":"0","endTime":"0","summary":"Needham analyst Joseph Stringer maintained a Buy rating on BioAge Labs, Inc. today and set a price target of $50.00. Joseph Stringer has given his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bioage-labs-bioa-phase-1-bge-102-data-reinforce-best-in-class-nlrp3-potential-and-de-risk-2026-cardiovascular-phase-2-supporting-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bioage-labs-bioa-phase-1-bge-102-data-reinforce-best-in-class-nlrp3-potential-and-de-risk-2026-cardiovascular-phase-2-supporting-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629031631","title":"BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2629031631","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629031631?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:30","pubTimestamp":1776774633,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) reported results from the Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant small molecule NLRP3 inh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-reports-results-for-phase-1-trial-of-bge-102-to-initiate-phase-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-reports-results-for-phase-1-trial-of-bge-102-to-initiate-phase-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629303660","title":"BioAge Shares Rise on Positive Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2629303660","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629303660?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:58","pubTimestamp":1776772680,"startTime":"0","endTime":"0","summary":"Shares of BioAge Labs were higher after the company shared positive data for a trial of its drug as a treatment for inflammation.The stock gained 9% to $20.49 in pre-market trading Tuesday. Through Monday's close, shares were up 42% this year.In a Phase 1 clinical trial, the drug BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein, a test of inflammation levels and cardiovascular risk.Patients dosed with 60 milligrams achieved reductions that were comparable to those who received a higher dose of 120 milligrams, the biopharmaceutical company said.Based on the results, BioAge plans to start a dose-ranging Phase 2 trial studying the drug as a treatment for cardiovascular risk. It intends to initiate the trial in the first half of 2026, with data anticipated in the second half of the year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"BioAge Shares Rise on Positive Trial Data","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629357730","title":"BioAge Labs Says Drug Candidate Shows 'Best-in-Class Reductions' in Inflammatory Biomarkers in Phase 1 Trial With Obese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2629357730","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629357730?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:44","pubTimestamp":1776771882,"startTime":"0","endTime":"0","summary":"BioAge Labs  said Tuesday its experimental BGE-102 drug demonstrated \"best-in-class reductions\" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.Shares of the company rose 9% in Tuesday's premarket activity.Price: 20.49, Change: +1.69, Percent Change: +8.99","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703382","title":"Bioage Labs: Reports Positive Phase 1 Data for Bge-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629703382?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769454,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41409Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603331","title":"Bioage Labs Inc - Phase 2 Cardiovascular Risk Trial to Initiate Mid-2026, Results Expected End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603331?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769454,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41409Y:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629333180","title":"Bioage Labs Inc - Bge-102 Well Tolerated Across All Dose Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2629333180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629333180?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769454,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41409Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629033876","title":"Bioage Labs Inc - Bge-102 Achieves ≥85% Median Hscrp Reductions at 120 Mg and 60 Mg Doses in Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2629033876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629033876?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769454,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41409Y:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629038085","title":"BioAge reports Phase 1 data for BGE-102, showing 85% hsCRP reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2629038085","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629038085?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:02","pubTimestamp":1776769339,"startTime":"0","endTime":"0","summary":"BioAge reported positive Phase 1 results for BGE-102, an oral NLRP3 inhibitor, showing strong reductions in inflammation markers in participants with obesity and elevated baseline inflammation.Data released included a newly disclosed 60 mg once-daily cohort, with outcomes described as comparable to previously reported results from a higher-dose group.BGE-102 was described as well tolerated across evaluated doses, supporting continued investment to advance the program.BioAge plans to start a Phase 2 dose-ranging cardiovascular risk proof-of-concept trial in first half of 2026, with results expected in second half of 2026.Company also plans a Phase 1b/2a proof-of-concept trial in diabetic macular edema in mid-2026, with results expected mid-2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLbVVjnM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210150020.SGD","BK4007","BIOA","IE00BN0W2W23.USD","BK4112","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","BK4588","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627465541","title":"BioAge Labs to present at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627465541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627465541?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:30","pubTimestamp":1776112252,"startTime":"0","endTime":"0","summary":"BioAge Labs will present at 25th Annual Needham Virtual Healthcare Conference on April 13-16, 2026.CEO Kristen Fortney is scheduled for fireside chat on April 16, 2026, from 3:00 PM to 3:30 PM EDT.CFO Dov Goldstein, Chief Strategy Officer BJ Sullivan will hold one-on-one investor meetings during conference.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDLbrDQwK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4585","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4007","SG9999014021.USD","BK4112","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624966489","title":"BioAge Labs CMO Paul D. Rubin disposes of common shares worth $0.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624966489","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624966489?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:07","pubTimestamp":1775246878,"startTime":"0","endTime":"0","summary":"BioAge Labs Chief Medical Officer Paul D. Rubin reported sale of 8,820 shares on April 1, 2026.Rubin ended day with 0 shares beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL8p1H5j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioAge Labs CMO Paul D. Rubin disposes of common shares worth $0.2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823007","title":"Needham Initiates BioAge Labs at Buy With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823007","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823007?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:22","pubTimestamp":1774610527,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) has an average rating of overweight and mean price target of $53.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823602","title":"Bioage Labs Inc : Needham Initiates Coverage With Buy Rating; Target Price $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823602?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:08","pubTimestamp":1774609690,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0ET:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622647823","title":"BioAge Labs Initiated at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2622647823","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622647823?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:04","pubTimestamp":1774609440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BIOA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 07:04 ET (11:04 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845792","title":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622845792?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:54","pubTimestamp":1774598066,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex HoldingsMarch 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4N40F0FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLU","UNX","GOOGL","BIOA","MASI","CHRD","LBRX","PHAT","MGTX","COP","PRMB","GGLS","BALY","LU1815333072.USD","OXY","HAL","KOD","ATAI","GOU","ADP","GOOW","IMMX","GGLL","FISV","OLPX","BK4561","U","EOG","GOOX","LU0345769128.USD","AGX","DIS","BK4551","OXM","CTAS","CMC","GOOP","CCL","FOXA","IT","SPXC","NHI","GOOY","DISO","PL","BK4134","GNRC","BTGO","KYIV","IE00BMPRXQ63.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622702014","title":"BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2622702014","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622702014?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:16","pubTimestamp":1774437366,"startTime":"0","endTime":"0","summary":"Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on BioAge Labs, Inc., retaining the price target of $23.00. Michael Ulz has given hi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bioage-labs-early-stage-promise-in-apj-agonists-balanced-by-execution-risk-supports-hold-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bioage-labs-early-stage-promise-in-apj-agonists-balanced-by-execution-risk-supports-hold-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","SSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622013770","title":"BioAge Labs files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013770","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013770?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:25","pubTimestamp":1774383915,"startTime":"0","endTime":"0","summary":"16:23 EDT BioAge Labs (BIOA) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622136560","title":"Bioage Labs Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622136560","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622136560?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:23","pubTimestamp":1774383806,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622136650","title":"BioAge Announces Lead Program BGE-102 NLRP3 Inhibitor Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622136650","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622136650?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:23","pubTimestamp":1774383799,"startTime":"0","endTime":"0","summary":"BioAge reported the nomination of BGE-102 as its lead program, positioning it as a potential driver for advancing the company’s pipeline in metabolic diseases.Issued patents covering composition of matter and a unique binding site were cited as an element of competitive positioning for the program.BioAge said it plans to pursue development of BGE-102 in two areas, cardiometabolic disease and ophthalmology, indicating a multi-indication commercial strategy.The company reported BGE-102 was well-tolerated in Single Ascending Dose and initial Multiple Ascending Dose cohorts, which could support continued clinical progression.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate thi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL2PZktc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622904280","title":"Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622904280","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622904280?lang=en_us&edition=fundamental","pubTime":"2026-03-25 03:00","pubTimestamp":1774378837,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA). ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioage-labs-inc-bioa-and-establishment-labs-holdings-esta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioage-labs-inc-bioa-and-establishment-labs-holdings-esta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","XLV","BIOA","BK4588","LABU","HCSG","LU0029874061.USD","LU2324357040.USD","BK4581","LU0128526141.USD","BK4198","BK4007","ESTA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":105,"code":"91000000","status":"200"}]}}